side effects glp 1 receptor agonists The cardiovascular of GLP-1 beyond obesity and type 2 diabetes: An anti-atherosclerotic action The expanding role of GLP-1
Description
2024;11:e146625
Val8-glucagon-like peptide-1 protects against A1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats
The FDA has officially approved oral semaglutide as the first GLP-1 pill specifically indicated for weight loss
doi: 10.1016/0167-0115(95)00167-0
J.HayesM
The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis
